![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, January 05, 2018 8:53:00 AM
I love this quote from our VP of Sales,
"We commend this move by the NHS, as this will open up the doors for reimbursement in the US and other managed care markets. This will likely have a tremendous impact on our sales and marketability of the product in the UK and elsewhere".
And this one from the mHealth Intelligence article showing how BIEL's efforts in 2017 are now paying off,
"BioElectronics officials say NHS approval was linked to a study in which treatment with the mHealth wearable helped reducers reduce their trips to the doctor’s office by almost 60 percent and cut prescription drug costs by 35 percent, resulting in an overall reduction in healthcare costs of 45 percent."
With all major healthcare providers struggling to do more for their customers while containing expenses how could any of them not consider the savings of providing ActiPatch for pain management.
https://mhealthintelligence.com/news/uk-approves-wearable-mhealth-device-for-chronic-pain-management
http://www.nasdaq.com/press-release/bioelectronics-actipatch-drug-free-pain-therapy-receives-united-kingdom-national-health-system-20180104-00229
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM